EFPIA Calls on EU Policy-makers to Set in Place a Strong and Attractive Paediatric Framework for the Benefit of Children
Taking part in a lunch debate organised by the European Parliament on the theme "Better Medicines for Children - The currently debated legislative proposal", Brian Ager, Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA), today called on EU policy-makers to quickly adopt the Commission's proposal for a Regulation on Medicinal Products for Paediatric Use.
Brussels, 27 April 2005 - Taking part in a lunch debate organised by the European Parliament on the theme "Better Medicines for Children - The currently debated legislative proposal", Brian Ager, Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA), today called on EU policy-makers to quickly adopt the Commission's proposal for a Regulation on Medicinal Products for Paediatric Use.
"The European-based pharmaceutical companies that invest in high value-creating R&D support this long-awaited EU initiative, said Brian Ager. Measures to be introduced at Community level must include simple and effective incentives to stimulate paediatric R&D in Europe".
Sharing EFPIA's views with high-level representatives of the European Parliament, the Presidency of the EU Council, the European Commission and various stakeholders, Brian Ager stressed that:
- so far progress has been achieved in numerous paediatric therapeutic fields, thanks to medicines that provide cure or relief from many childhood diseases;
- but pharmaceutical research in children presented a series of scientific, technical, practical and ethical challenges of importance;
- industry, regulators, patient groups, doctors, paediatric societies and EU researchers all had a role to play - the goal was to foster paediatric research in Europe for the benefit of children.
The adoption of the Commission's proposal by the European Parliament and the European Council and subsequently its implementation without delay by all EU-25 Member States is a key opportunity to improve children's health. It should also allow Europe to catch up with other world regions where paediatric research has been incentivised as a means to develop medicines adapted to the needs of children.
"Our children must be able to benefit from medicines tailored to their special needs. This must be achieved by restoring a strong pharmaceutical research and development presence for Europe", concluded Brian Ager.
EFPIA's views on the European Commission's Proposal for a Regulation on Medicinal Products for Paediatric use are available on-line on the EFPIA website at: http://www.efpia.org/4_pos/paediatrics0405.pdf
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
